Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc. News
Bellerophon Therapeutics, Inc. Quantitative Score
About Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Bellerophon Therapeutics, Inc. Earnings & Revenue
Bellerophon Therapeutics, Inc. Financials
Table Compare
Compare BLPH metrics with: | |||
|---|---|---|---|
Earnings & Growth | BLPH | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BLPH | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BLPH | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BLPH | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Bellerophon Therapeutics, Inc. Income
Bellerophon Therapeutics, Inc. Balance Sheet
Bellerophon Therapeutics, Inc. Cash Flow
Bellerophon Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Bellerophon Therapeutics, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.0190 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| TBA | 0.018965 | Quarterly |
Bellerophon Therapeutics, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Bellerophon Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Mr. Craig R. Jalbert CIRA | President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Craig R. Jalbert CIRA | President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director | Male | 1962 | -- |
Bellerophon Therapeutics, Inc. Insider Trades
| Date | 13 Oct |
| Name | Puissance Capital Management LP |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1076841 |
| Date | 7 Jun |
| Name | Amin Naseem |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 47578 |
| Date | 7 Jun |
| Name | Fernandes Peter |
| Role | See Remarks |
| Transaction | Disposed |
| Type | A-Award |
| Shares | 100000 |
| Date | 7 Jun |
| Name | Shah Parag Suresh |
| Role | VP of Business Operations |
| Transaction | Disposed |
| Type | A-Award |
| Shares | 50000 |
| Date | 7 Jun |
| Name | Dekker Martin |
| Role | See Remarks |
| Transaction | Disposed |
| Type | A-Award |
| Shares | 50000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 13 Oct | Puissance Capital Management LP | 10 percent owner | Disposed | S-Sale | 1076841 |
| 7 Jun | Amin Naseem | Director | Acquired | A-Award | 47578 |
| 7 Jun | Fernandes Peter | See Remarks | Disposed | A-Award | 100000 |
| 7 Jun | Shah Parag Suresh | VP of Business Operations | Disposed | A-Award | 50000 |
| 7 Jun | Dekker Martin | See Remarks | Disposed | A-Award | 50000 |